| scholarly article | Q13442814 |
| P50 | author | Yo-Ichi Yamashita | Q87697102 |
| Maximiliano Gelli | Q87713269 | ||
| Marc-Antoine Allard | Q88325630 | ||
| Katsunori Imai | Q90245729 | ||
| P2093 | author name string | S Yamashita | |
| K Hasegawa | |||
| D Elias | |||
| H Baba | |||
| R Adam | |||
| Y Nishioka | |||
| D Cherqui | |||
| E Vibert | |||
| Y Kitano | |||
| T Kokudo | |||
| A Sa Cunha | |||
| D Goere | |||
| N Beghdadi | |||
| P2860 | cites work | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial | Q24647888 |
| Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey. | Q30930073 | ||
| Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial | Q34656647 | ||
| Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial | Q36121535 | ||
| Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies | Q36225803 | ||
| Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples | Q36319710 | ||
| Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. | Q36324953 | ||
| Constructing inverse probability weights for marginal structural models | Q37321459 | ||
| Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases | Q37500453 | ||
| The role of preoperative chemotherapy in patients with resectable colorectal liver metastases | Q37530660 | ||
| Chemotherapy before liver resection of colorectal metastases: friend or foe? | Q37951267 | ||
| Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis | Q38024277 | ||
| Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis | Q39466085 | ||
| Factors influencing recurrence following initial hepatectomy for colorectal liver metastases | Q39680526 | ||
| An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies | Q41962966 | ||
| FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. | Q43099186 | ||
| Confidence limit analyses should replace power calculations in the interpretation of epidemiologic studies | Q43716214 | ||
| Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. | Q43880882 | ||
| R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? | Q45674652 | ||
| Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases? | Q46113484 | ||
| Remnant liver volume to body weight ratio > or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver | Q47308498 | ||
| Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases. | Q50943779 | ||
| Calculation of child and adult standard liver volume for liver transplantation. | Q52342275 | ||
| The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. | Q52373114 | ||
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. | Q52861120 | ||
| A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. | Q53004091 | ||
| Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect | Q60629731 | ||
| The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. | Q64984888 | ||
| Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer | Q87165322 | ||
| Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure | Q87239062 | ||
| Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis | Q87416575 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 678-686 | |
| P577 | publication date | 2019-05-14 | |
| P1433 | published in | BJS Open | Q73378415 |
| P1476 | title | Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases | |
| P478 | volume | 3 |
Search more.